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ABSTRACT 
Objective: Liver cirrhosis is a health care problem in Egypt caused by the high prevalence of hepatitis C virus (HCV) infection that affects 15-20 % 
of the population. Cirrhotic cardiomyopathy is the term used to describe a constellation of features indicative of abnormal heart structure and 
function in patients with cirrhosis.  
Aim of this study is to assess the pattern and the extent of cardiac affection in cirrhotic patients and its relation to the presence or absence of ascites.  
Medthods: This study was carried out on 70 patients with liver cirrhosis and 30 healthy controls. All persons were subjected to careful history & 
physical examination, laboratory investigations, abdominal ultrasonography,and echocardiography.  
Results: left ventricle end diastolic diameter was significantly increased in cirrhotic patients with ascites (5.40±0.58) and without ascites 
((5.31±0.51), compared to the control group (4.52±0.58) (p<0.05),. left ventricle end systolic diameter was increased in cirrhotic patients with 
ascites (3.57±2.2) and without ascites (3.46±3.1), without ascites (3.18±2.5)but the difference was statistically non significant (p > 0.05). Left 
atrium diameter & Right ventricular end diastolic diameter were significantly increased in cirrhotic patients compared to the control group (p<0.05 
The pulmonary artery pressure was elevated in cirrhotic patients compared to the control group..  
Conclusion: In the present study Liver cirrhosis is associated with significant enlarged cardiac chambers and. diastolic dysfunction compared to the 
control group specially in the presence of ascites. 
Keywords: Cirrhosis, Ascites, Echocardiography Cardiomyopathy diastolic dysfunction 
 
INTRODUCTION 
Liver cirrhosis is a health care problem in Egypt caused by the high 
prevalence of HCV infection that affects 15-20 % of the general 
population [1]. Liver cirrhosis is associated with a wide range of 
cardiovascular abnormalities including hyperdynamic circulation, 
enlargement or hypertrophy of different cardiac chambers and 
electrophysiological changes such as QT prolongation [2]. In 
cirrhosis, despite the increased basal cardiac output, cardiac 
response to physiologic or pharmacologic stimuli is known to be 
subnormal a phenomenon called cirrhotic cardiomyopathy. The 
pathogenesis of cirrhotic cardiomyopathy is multifactorial and still 
incompletely defined; it includes abnormalities in the b-adrenergic 
signaling pathway, altered cardiomyocyte membrane fluidity, 
increased myocardial fibrosis, cardiomyocyte hypertrophy and ion 
channel defects [3]. Accumulating evidence suggests that cirrhotic 
cardiomyopathy plays a major role in the pathogenesis of cardiac 
dysfunction following liver transplantation or trans-jugular intra-
hepatic porto-systemic shunt placement and contributes to the 
pathogenesis of hepatorenal syndrome [2]. Recognition of cirrhotic 
cardiomyopathy will depend on a high level of awareness and 
potentially will help better management of patients with cirrhosis 
[4]. 
Aim of the work 
The aim of this work is to study the pattern and the extent of cardiac 
affection in cirrhotic patients and its relation to the presence or 
absence of ascites. 
MATERIALS AND METHODS 
This study was done in the department of internal medicine, Fayoum 
teaching hospital; it was carried on 30 patients with liver cirrhosis 
and without ascites (10 females and 20 males) (Group -1), 40 
patients with liver cirrhosis and ascites ( 12 females and 28 males) 
(Group - 2), and 30 healthy controls ( 14 females and 16 males) 
(Group - 3). Inclusion criteria : Patients diagnosed with liver 
cirrhosis depending on clinical evidence of stigmata of chronic liver 
disease (e.g. jaundice, ascites, palmer erythema, etc) and 
ultrasonographic coarse echo texture and shrunken liver. Exclusion 
criteria: Patients with cardiovascular diseases e.g. hypertension, 
ischemic heart disease, valvular heart disease and atrial fibrillartion, 
patients with severe anemia, renal failure and diabetes mellitus. 
Each person included in the study was subjected to Careful 
history taking and thorough physical examination. 
 
Laboratory investigations 
Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), 
serum alkaline phosphatase, serum albumin, Prothrombin 
concentration, total and direct bilirubin and hepatitis markers for 
HBV and HCV 
Abdominal ultrasonography 
 
Using GE LOGIQ9 apparatus (GE Healthcare., Milwaukee, WI) with a 
2–5 MHz convex array transducer (low frequency probe) and a 5–12 
MHz convex array transducer (high frequency probe).recording both 
static and B-mode imaging in the fasting state. Series of images of 
both lobes of the liver were obtained for evaluation of the 
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parenchymal echo texture, focal lesions, volumetric changes, and 
edge evaluation. High-resolution images of the surface of the right 
and left lobes of the liver were obtained with high-frequency probes 
for evaluation of the surface of the liver. Additional images were 
obtained if required to assess portal tracts as well as and splenic 
veins and assessment of size of the spleen and the presence of 
ascites or retroperitoneal masses.  
 
Standard twelve-lead electrocardiogram (12-lead ECG) 
 
For assessment of cardiac rhythm and features suggesting of 
chamber enlargement or coronary artery disease (CAD). 
 
Echo Doppler study 
 
Echocardiography was performed using and ACUSON CV70 machine 
equipped with a 2.5/3.25 MHz annular array transducer. Patients 
underwent a complete echocardiographic examination including 2-D 
transt-horacic imaging, pulsed wave Doppler, continuous wave 
Doppler, and color flow mapping. The patients were monitored 
through a single-lead electrocardiogram. LV internal dimension, left 
ventricular end-diastolic (LVEDD) and end-systolic (LVESD) 
interventricular septal thickness (IVS), posterior wall thickness 
(PWT), right ventricular end-diastolic (RVEDD) and end-systolic 
(RVESD) and left atrium (LA) end-systolic diameter were obtained; 
left ventricular EF was calculated by Simpson's biplane method of 
discs. Pulsed wave Doppler echocardiography was used to evaluate 
trans-mitral LV filling velocities at the tips of the mitral valve leaflets 
and trans-tricuspid RV filling velocities at the tips of the tricuspid 
valve leaflets on the apical four chamber view and the peak early 
diastolic flow velocities (E), the peak of atrial flow velocities (A) and 
the ratio of E/A were determined. Color Doppler interrogation of 
mitral regurgitant jet in 2 orthogonal views to assess the severity of 
MR (mild MR: mean color flow jet area in the left atrium <4cm2; 
moderate MR: mean color flow jet area 4 to 8cm2, mean color flow 
jet area > 8 cm2) and TR jet to assess the severity of TR (mild TR: 
mean color flow jet area in the right atrium <5cm2; moderate TR: 
mean color flow jet area 5 to 10 cm2; severe TR: mean color flow jet 
area > 10 cm2).Pulmonary arterial pressure (PAP) was calculated 
pulmonary artery systolic pressure using the simplified Bernoulli 
equation from the velocity of the TR jet and RA pressure [5]." 
STATISTICAL ANALYSIS 
Collected data were computerized and analyzed using Statistical 
Package for Social Science (SPSS) version 16. Descriptive statistics 
were used to describe variables; percent, proportion for qualitative 
variables. Mean ± SD and range for Quantitative variables. Student’s 
t-test was used to compare the normally distributed continuous 
variable between the patients with aortic valve stenosis and the 
healthy control group. Fisher-exact test and Chi-square test were 
used to compare categorical variables. P values with significance of 
less than 5% were considered statistically significant. For all 
statistical tests, a P value less than 0.05 was  used to indicate 
significance. 
RESULTS 
This study was done in Fayoum university hospital; it was carried on 
30 liver cirrhosis patients without ascites (Group -1), 40 liver 
cirrhosis patients with ascites (Group- 2), and 30 healthy controls 
(Group- 3).  
Group - 1: Included 10 female and 20 male patients with mean age 
46.9 ± 7.2 years, 22 patients had HCV infection, 8 patients had HBV, 
9 patients had jaundice, 4 patients had hematemesis,3 patients had 
melena and non of the patients were alcoholic.  
Group - 2: Included 12 female and 28 male patients with Included 
10 female and 20 male patients with mean age 48.3 ± 4.4 years, 30 
patients had HCV infection, 10 patients had HBV, 24 patients had 
jaundice, 26 patients had hematemesis,10 patients had melena, 35 
patients had pitting edema of lower limbs and non of the patients 
were alcoholic.  
Group - 3: Included 14 female and 16 male normal subjects with 
mean age 49.5 ± 4.5 years and normal parameters of all liver 
function tests. There was significantly lower serum albumin & PC 
level in group - 2 patients compared to group -1 ( p< 0.001 ).On the 
other hand, there was higher total and direct bilirubin level and 
prolonged PT in patients with group - 2 compared to group - 1 ( p< 
0.001 )  
Mean LVEDD was significantly increased in group -1 (5.28 ± 0.51 
mm) and in group - 2 (5.41 ± 0.58 mm) compared to group -3 
(4.72±0.58 mm) and the difference was statistically significant (p< 
0.05). Mean LVESD was 3.46±3.1 mm in group 1; 3.57 ± 2.2 mm in 
group 2 and 3.28 ± 2.5 mm in the control group and the difference 
was not statistically significant ( p>0.05 ). Mean LV ejection fraction 
was 60 ± 4.56 % in group - 1; %, 61 ± 6.61% in group - 2 compared 
to 60.6 ± 1.9% in the control group and the difference was 
statistically insignificant (p> 0.05 ).LA diameter in end-systole was 
found to be larger in group - 1;4.46 ± 0.4 mm and in group 2, 4.72 ± 
0.44 mm vs. 2.98 ±0.31 in the control group) ( p< 0.001 ). RV size 
was found to be larger in group - 1; 3.03±0.57 mm and in group - 2; 
3.66±0.37 mm compared to 1.95±0.13 mm in control group (p< 
0.001). Mean PAP was found to be higher in patients of group 1; 
25.38±6.94 mmHg and in patients of group 2, 39.29±7.1mmHg vs. 
13.2±1.93 mmHg in the control group) (p< 0.001) as shown in table 
[1]. 
Mitral valve E/A ratio < 1 was found in 12 patients of group - 1, 30 
patients of group - 2 compared to only one of the control group and 
the difference in E/A ratio was statistically highly significant ( p < 
0.001) as shown in table [2]. 
Tricuspid valve E/A ratio < 1 was found in 7 patients of group - 1, 35 
patients of group - 2 compared to only two persons of the control 
group and the difference in E/A ratio was statistically highly 
significant ( p < 0.001) as shown in table [2]. 
Univariate regression analysis revealed significant correlations 
between LV diastolic dysfunction and age (r=0.239, p <0.001), 
presence of ascites (r=0.155, p =0.002), RV enlargement (r=0.123, p 
=0.037) and pulmonary hypertension (r=0 0.190, p =0.005) as 
shown in table [3]. 
Univariate regression analysis revealed significant correlations 
between RV diastolic dysfunction and presence of ascites (r=0.154, p 
=0.004), right ventricular enlargement r=0.161, p =0.015) and 
pulmonary hypertension (r=0 0.211, p =0.001) as shown in table [3]. 
DISCUSSION 
Liver cirrhosis is associated with a wide range of cardiovascular 
abnormalities including hyperdynamic circulation, cirrhotic 
cardiomyopathy, and pulmonary vascular abnormalities [6]." 
Cirrhotic cardiomyopathy is a clinical syndrome in patients with 
liver cirrhosis characterized by an abnormal and blunted response 
to physiologic, pathologic, or pharmacologic stress but normal to 
increased cardiac output and contractility at rest. As many as 50% of 
cirrhotic patients undergoing liver transplantation show signs of 
cardiac dysfunction, and 7% to 21% of deaths after orthotopic liver 
transplantation result from overt heart failure [7]." Strict diagnostic 
criteria for cirrhotic cardiomyopathy are lacking and the presence of 
this syndrome should be suspected in patients with worsening 
hemodynamic [8]."  
Our study included 30 liver cirrhosis patients without ascites and 40 
liver cirrhosis patients with ascites and fulfilling the criteria of liver 
cirrhosis diagnosed clinically by the stigmata of chronic liver disease 
and ultrasonographically by shrunken liver and coarse echo texture. 
We found that, patients with liver cirrhosis had higher LVEDD when 
compared to control group (P < 0.05) and there was no significant 
difference in the LV EF % in patients with liver cirrhosis when 
compared to control group (P > 0.05). Left ventricular EF has been 
reported to be normal in some studies [9,10]." increased in others 
[11,12,13]." and decreased only in one study of patients with 
cirrhosis and ascites [14].". A relative increase in the EF of patients 
with cirrhosis could be explained by the hyperdynamic circulation as 
a result of splanchnic vasodilatation.LV systolic function is usually 
normal at rest and systolic incompetence is most evident under 
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stress, whether physical or pharmacological, or when the extent of 
peripheral arterial vasodilatation demands an increased cardiac 
output as in the case of bacterial infections. Acute volume overload 
after insertion of a trans-jugular intra-hepatic porto-systemic shunt 
or after liver transplantation can also precipitate LV systolic 
dysfunction [6]." In our study, we found that patients with liver 
cirrhosis had higher LA diameter and RVEDD when compared to 
control group (P < 0.001).Our results came in agreement with 
Papastergiou et al., 2012 [15]. who found echocardiographic 
evidence of mild to moderate left atrium enlargement was found in 
36% of the studied population. Significant correlation between left 
atrial size and intrapulmonary right to left shunt, characterizing 
hepatopulmonary syndrome was observed in a previous report 
[16]." Furthermore Valeriano et al., 2000 [17] " found that right and 
left atrium and right ventricular diameters were significantly 
enlarged in cirrhotic patients versus controls. These abnormal 
structural findings in cirrhotic patients seem to be an adaptation of 
cardiac hemodynamic to the changes in the peripheral circulation 
and thus the role of the rennin-angiotensin-aldosterone system 
(RAAS) and adrenergic hyperactivity has been considered. In 
addition Wong, 2009 [2] found an increased diameter of the left 
atrium and some degree of diastolic dysfunction in 39 pre-ascitic 
and ascitic patients and concluded that ascitic patients had a thicker 
left ventricular wall and a lower E/A ratio, indicating greater 
impedance to venous return than pre-ascitic cirrhotic patients. 
In our study, we found significant abnormalities in both left and 
right ventricular diastolic function in patients with liver cirrhosis in 
the form of reversed E/A ratio with significant decrease in E wave 
average velocity of both mitral and tricuspid annulus with reversed 
E/A ratio. LV diastolic dysfunction was detected in 12 patients with 
liver cirrhosis without ascites and 30 patients with ascites and 
correlated with age (r=0.239, p <0.001), presence of ascites 
(r=0.155, p=0.002),right ventricular enlargement (r=0.123, p 
=0.037) and pulmonary hypertension (r=0 0.190, p =0.005).RV 
diastolic dysfunction was detected in 7 patients with liver cirrhosis 
without ascites and 35 patients with ascites and correlated with 
presence of ascites (r=0.154, p =0.004), right ventricular 
enlargement r=0.161, p =0.015) and pulmonary hypertension (r=0 
0.211, p =0.001). 
In our study, diastolic dysfunction appears to be more common in 
cirrhotic patients with ascites than those without ascites and that 
some degree of diastolic dysfunction is present in the majority of 
patients with cirrhosis. Right ventricle diastolic dysfunction may be 
due to the decrease in cardiac preload, increase in the afterload or 
right ventricular relaxation or other abnormalities in compliance 
[18]. Left ventricle Diastolic dysfunction is often linked to cardiac 
structure abnormalities including a combination of myocardial 
hypertrophy, fibrosis, and subendothelial edema [19]. The stiff and 
noncompliant ventricles cannot accommodate the venous return to 
the heart in early and middle-late diastole. Significant stimulus may 
not be required to precipitate diastolic dysfunction so that 
echocardiography may reveal abnormal diastolic function even at 
rest. Functional component cannot be also excluded, as 
improvements in diastolic dysfunction have been reported after 
paracentesis in patients with tense ascites and port systemic shunt 
insertion [20." Decrease in cardiomyocyte metabolism have been 
recently proposed in order to explain diastolic dysfunction and its 
reversibility after liver transplantation [15]."  
Our results came in agreement with Salari et al., [21] who reported 
that diastolic dysfunction was significantly present in all cirrhotic 
patients but the severity was increased with the increased severity 
of the chronic liver disease. Møller et al., 2006 [11] showed that A 
wave velocities and deceleration times are much increased and the 
E/A-ratio is decreased in cirrhotic patients, especially in those with 
ascites. Pozzi et al., 1997 [14] found that in cirrhotic patients with 
tense ascites, the A wave velocity is markedly increased, the E/A 
ratio is markedly reduced, and the deceleration time is significantly 
prolonged. Furthermore, removal of the ascitic fluid by rapid total 
paracentesis was associated with reduction in A wave velocity and 
increases the E/A ratio to values similar to those of cirrhotic patients 
without ascites but still abnormal as compared with healthy 
controls. 
Another important finding in our study was the significantly higher 
pulmonary artery pressure in liver cirrhosis patients (25.38±6.94 
mmHg in patients without ascites, 39.29±7.1 mmHg in patients with 
ascites and 13.2±1.93 mmHg in controls, p<0.001).In fact, 
pulmonary vascular resistance was tended to decrease in cirrhotic 
patients. The mechanism of increased PAP is not fully understood, 
but previous studies suggested the increased levels of vasoactive 
substances in pulmonary circulation and the probable toxic effect of 
these substances on endothelial cells [18 ]." Some authors have 
suggested that microthrombi can migrate to pulmonary vascular bed 
along porto-systemic shunts and can cause increase in vascular 
resistance [22].".  
 
LIMITATIONS OF THE STUDY 
The number of the patients was not large enough to have more 
valuable correlation between the severity of the disease and the 
prevalence of cardiovascular abnormalities. more sophisticated 
echocardiographic tools (e.g., tissue Doppler imaging), which could 
have increased the reliability of our results, were not used. We 
cannot rule out the decreased cardiac reserve in stress conditions 
because we evaluated all of our patients in the resting position.  
CONCLUSION 
Liver cirrhosis is associated with echocardiographic changes in the 
form of enlarged right cardiac chambers, diastolic dysfunction and 
pulmonary hypertension and these changes are more evident in 
cirrhotic patients with ascites than those without ascites. 
Echocardiography should be part of the screening of patients with 
chronic liver disease, because patients with systolic and / or 
diastolic dysfunction and porto-pulmonary hypertension could be at 
higher morbidity and mortality risk. 
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Table 1: Echocardiographic findings in the study groups 
Parameter Group 1 Group 2 Group 3 
IVS 0.85 ± 0.11 0.81±0.12 0.82±0.14 
P > 0.05 P > 0.05  
PWT 0.78 ± 0.09 0.79±0.10 0.77±0.12 
P > 0.05 P > 0.05  
LVEDD (n: 3.7-5.6cm) 5.31±0.51 5.40±0.58 4.52±0.58 
P < 0.05 P < 0.05  
LVESD (n: 24-37mm) 3.46±3.1 3.57±2.2 3.18±2.5 
P > 0.05 P > 0.05  
EF% (n: 55- 75%) 60±4.56 61±6.61 60.6±1.9 
P > 0.05 P > 0.05  
LA size (n: 1.9- 4 cm) 4.46±0.4 4.72±0.44 2.98±0.31 
P < 0.001 P < 0.001  
RVEDD (n: 0.7- 5.6cm) 3.03±0.57 3.66±0.37 
 
1.95±0.13 
P < 0.05 P < 0.001 
 
 
PAP (n: 12-28mmHg) 25.38±6.94 39.29±7.1 
 
13.2±1.93 
P < 0.05 P < 0.001 
 
 
 IVS=inter ventricular septum thickness in diastole; PW= posterior wall thickness in diastole, LVEDD= left ventricular end diastolic diameter; 
LVESD= left ventricular end systolic diameter ;EF%,= ejection fraction; LA= left atrium diameter in end systole; RVEDD= right ventricular end 
diastolic diameter ;PAP= peak pulmonary artery pressure  
Table 2: Prevalence of diastolic dysfunction among the study groups 
  
E/A ratio 
Group 1 Group 2 Group3 
No % No % No % 
 Mitral valve 
(LVDD) 
 
Normal E/A ratio 18 60% 10 25% 29 96.7 




Normal E/A ratio 23 69 % 5 12.5 % 28 93.3% 
Reversed E/A ratio 7 21% 35 87.5% 2 6.7% 
 E= mitral valve early diastolic velocity; A=mitral valve late diastolic velocity. 
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Table 3 : Correlations of LV & RV diastolic dysfunction with different parameters in cirrhotic patients 
 LV Diastolic dysfunction RV Diastolic dysfunction 
Variables r P. value r P. value 
AgeAge 0.239  0.001  0.062  0.17 
Jaundice 0.115   0.10 0.078  0.11 
Hematemesis 0.035  0.58 0.011  0.86 
 
Melena 0.064  0.32 0.033  0.57 
Ascites 0.155  0.002  0.154  0.004  
AST  0.081  0.16 0.022  
 
 0.73 
ALT  0.043   0.51 0.038  
 
0.42 
Serum albumin 0.007  0.90 0.009  0.89 
 
PT 0.064  0.32 0.050  0.48 
 
LVEDD 0.142  0.042 0.062  
 
 0.17 
LVESD 0.105  0.081 0.078  0.11 
 
EF 0.068  0.24 0.058 0.26 
 
LA Diameter 0.104   0.13 0.089  0.15 
 
RVEDD 0.123  0.037  0.161 
 
0.015  
PAP 0.190  0.005  0.211  
 
 0.001  
 AST=Aspartate aminotransferase; ALT= Alanine aminotransferase; PT= prothrombin time; LVEDD= left ventricular end diastolic diameter; LVESD= 
left ventricular end systolic diameter ;EF%,= ejection fraction; LA= left atrium diameter in end systole; RVEDD= right ventricular end diastolic 
diameter ;PAP= peak pulmonary artery pressure  
Table  4: Mitral & tricuspid valve diastolic inflow velocities in the study groups 

























E Wave  57.5 ± 1.2  56.2 ± 1.1 58.4 ± 2.1  
P > 0.05 
 
P > 0.05  
A Wave 60.3 ± 2.9 
 
62.8 ± 1.2 51.8 ± 11.2 
P < 0.05 
 
P < 0.05  
E/A ratio 0.95± 0.6 
 
0.94 ± 0.8 1.21 ± 0.42 
P < 0.001 
 



























E Wave  45.25±1.30 40.11±2.70 50.31±1.23 
P < 0.001 P < 0.001  
A Wave 47.22±2.12 50.66±2.27 43.22±1.62 
P = 0.02 P = 0.07  
E/A ratio 0.94±0.05 0.83 ± 0.07 1.25±0.05 
P < 0.001 P < 0.001  
23.   
Table 5: Comparison between liver biochemical tests in the study groups 
Parameter Group 1 Group 2 Group 3 
AST (n:up to 38mg/dl) 68.44±38.83 97.08±47.83 22.9±4.93 
P < 0.001 P < 0.001  
ALT (n:up to 40mg/dl) 38±20.08 59.79±29.79 21±5.3 
P < 0.001 P < 0.001  
ALP (n:40-180U/L) 185.25±93.77 221.58±89.84 116.3±20.69 
P < 0.001 P < 0.001  
Total protein(n:6.5-8.5g/dl) 6.73±0.49 5.63±0.65 7.78±0.64 
P < 0.001 P < 0.001  
Albumin (3.5-5gm/dl) 3.29±0.64 2.13±0.47 4.02±0.29 
P < 0.001 P < 0.001  
Total bilirubin(n: 0.2-1 mg/dl) 1.12±0.90 3.06±1.29 0.63±0.2 
P < 0.001 P < 0.001  
Direct bilirubin (n:0-0.2mg/dl) 0.31±0.14 1.26±0.78 0.06±0.03 
P < 0.001 P < 0.001  
PT (n:12sec) 15.34±2.23 29.72±10.47 12.4±0.38 
Mashahit et al. 




P < 0.001 P < 0.001  
PC (n: 80-100%) 59.21±12.34 45.67±11.56 93.4±5.25 
P < 0.001 P < 0.001  
 AST=Aspartate aminotransferase; ALT= Alanine aminotransferase; PT= prothrombin time; PC= prothrombin concentration;  
 
Hepatitis  C  VIRUS HCV 1 
QT  interval QT 2 
Beta – adrenergic  b-adrenergic 3 
Aspartate aminotransferase AST 4 
Alanine aminotransferase ALT 5 
Hepatitis  B  VIRUS HBV 6 
electrocardiogram ECG 7 
Coronary artery disease CAD 8 
Left  ventricle LV 9 
left ventricular end diastolic diameter LVEDD 10 
left ventricular end systolic diameter LVESD 11 
inter ventricular septum thickness in diastole IVS 12 
posterior wall thickness in diastole PWT 13 
right ventricular end diastolic diameter RVEDD 14 
right ventricular end systolic diameter RVESD 15 
left atrium diameter in end systole LA 16 
ejection fraction; EF 17 
RIGHT VENTRICLE RV 18 
the peak early diastolic flow velocities E 19 
the peak of late flow velocities   A 20 
Ratio of  E/A E/A 21 
Mitral  regurgitation MR 22 
Tricuspid regurgitation TR 23 
peak pulmonary artery pressure PAP 24 
Standard deviation SD 25 
Prothrombin concentration PC 26 
 Left ventricular diastolic dysfunction LVDD 26 
right ventricular diastolic dysfunction RVDD 27 
  
 
 
 
 
